Online inquiry

IVTScrip™ mRNA-Human ADAP1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK8910MR)

This product GTTS-WK8910MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADAP1 protein. This product can be used in Ciliated epithelial cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001284308.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 11033
UniProt ID O75689
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADAP1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK8910MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK28319MR IVTScrip™ mRNA-Human ARHGEF39, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARHGEF39
GTTS-WK23195MR IVTScrip™ mRNA-Human ARHGAP30, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP30
GTTS-WK26860MR IVTScrip™ mRNA-Human ARMCX3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARMCX3
GTTS-WK27069MR IVTScrip™ mRNA-Human ARFGAP1, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARFGAP1
GTTS-WK15826MR IVTScrip™ mRNA-Human ANKRD44, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANKRD44
GTTS-WK10795MR IVTScrip™ mRNA-Human AGC1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGC1
GTTS-WK21243MR IVTScrip™ mRNA-Human ANLN, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANLN
GTTS-WK25657MR IVTScrip™ mRNA-Human ARMC8, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARMC8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW